Breaking News Instant updates and real-time market news.

KRG

Kite Realty Group

$15.98

-0.305 (-1.87%)

, NHI

National Health Investors

$78.33

-1.74 (-2.17%)

04:55
05/21/19
05/21
04:55
05/21/19
04:55

Sandler O'Neill to hold company meetings at conference

Sandler O'Neill Company Meetings at RECon 2019 in Las Vegas on May 20-21.

KRG

Kite Realty Group

$15.98

-0.305 (-1.87%)

NHI

National Health Investors

$78.33

-1.74 (-2.17%)

SPG

Simon Property

$170.47

-3.95 (-2.26%)

CBL

CBL & Associates

$1.09

-0.135 (-11.02%)

BRX

Brixmor

$17.96

-0.16 (-0.88%)

KIM

Kimco Realty

$17.96

-0.12 (-0.66%)

ALEX

Alexander & Baldwin

$23.22

-0.03 (-0.13%)

UBP

Urstadt Biddle Properties Inc.

$17.80

(0.00%)

HHC

Howard Hughes

$105.79

-2.99 (-2.75%)

  • 30

    May

  • 31

    May

  • 04

    Jun

  • 04

    Jun

  • 04

    Jun

  • 11

    Jun

  • 25

    Jul

  • 30

    Jul

KRG Kite Realty Group
$15.98

-0.305 (-1.87%)

02/26/19
RAJA
02/26/19
DOWNGRADE
RAJA
Market Perform
Kite Realty Group downgraded to Market Perform from Outperform at Raymond James
02/26/19
02/26/19
DOWNGRADE

Market Perform
Kite Realty Group downgraded to Market Perform at Raymond James on asset sale
As previously reported, Raymond James analyst Collin Mings downgraded Kite Realty Group to Market Perform and removed his $20 price target. The analyst attributes the rating revision to the company's plans to sell up to $500M in assets to improve its portfolio quality and reduce leverage, suggesting that these efforts lag its peers. Mings further notes that while Kite Realty is maintaining its dividend payout, the payout ratio will be moving "materially higher" given the disposition activity and will become an overhang on investor sentiment as well as the company's redevelopment activity efforts.
03/04/19
BOFA
03/04/19
DOWNGRADE
BOFA
Underperform
Kite Realty Group downgraded to Underperform from Neutral at BofA/Merrill
02/04/19
LEHM
02/04/19
NO CHANGE
LEHM
Barclays upgrades U.S. REITs sector to Positive from Neutral
Barclays analyst Ross Smotrich upgraded his sector rating on U.S. Real Estate Investment Trusts to Positive from Neutral. Late cycle concerns around slowing growth, rising interest rates and full asset values are overdone, Smotrich tells investors in a research note. The analyst believes that real estate fundamentals "have a good runway for continued strength, particularly compared to the slowing broader market." In Multifamily, the analyst upgraded the sub-sector to Positive, reiterates Overweight ratings on Essex Property Trust (ESS) and MAA (MAA), upgraded Camden Property Trust (CPT) to Overweight from Equal Weight for exposure to "18 hour cities" and downgraded Aimco (AIV) to Equal Weight from Overweight on slowing growth. In Office, Smotrich keeps a Neutral sub-sector rating "with a Positive tilt." His outlook for the sector is improving given "healthy underlying fundamentals and attractive valuations." He upgraded both SL Green Realty (SLG) and Brandywine Realty (BDN) to Overweight from Equal Weight, and Douglas Emmett (DEI) to Equal Weight from Underweight. The analyst maintain Overweight ratings on Alexandria Real Estate (ARE), Boston Properties (BXP) and Hudson Pacific (HPP). In Retail, the analyst tells investors to stay selective. He prefers larger companies with "better-quality assets, balance sheet flexibility, the ability to take share and grow earnings even as retailers evolve and rationalization store counts." Smotrich upgraded Regency Centers (REG) to Overweight from Equal Weight, reaffirmed Overweights on both Kimco Realty (KIM) and Simon Property (SPG), and downgraded Kite Realty Group (KRG) to Equal Weight from Overweight.
NHI National Health Investors
$78.33

-1.74 (-2.17%)

05/31/18
WELS
05/31/18
NO CHANGE
Target $75
WELS
Market Perform
National Health Investors price target raised to $75 from $68 at Wells Fargo
Wells Fargo analyst Todd Stender raised his price target for National Health Investors to $75 from $68 on valuation, while reiterating a Market Perform rating on the shares.
02/20/19
BMOC
02/20/19
DOWNGRADE
BMOC
Underperform
National Health downgraded to Underperform from Market Perform at BMO Capital
02/20/19
RHCO
02/20/19
NO CHANGE
Target $85
RHCO
Hold
National Health Investors price target raised to $85 from $79 at SunTrust
SunTrust analyst Eric Fleming raised his price target on National Health to $85 after its Q4 results and 2019 guidance, saying that while a few tenant issues pressured the quarter, the REIT offers "one of the lowest levered balance sheets in the healthcare" space. The analyst is also keeping his Hold rating on National Health, noting that although its growth outlook is stable, the company's premium valuation relative to its senior housing/skilled nursing warrants a neutral stance.
08/08/18
RHCO
08/08/18
NO CHANGE
Target $79
RHCO
Hold
National Health Investors price target raised to $79 from $73 at SunTrust
SunTrust analyst Eric Fleming raised his price target on National Health Investors to $79 after its Q2 results, saying the company's "disciplined approach" has resulted in a stable portfolio driving "steady" results. Fleming notes that tenant expenses "bear watching", but also points to a "generally improving outlook across the senior housing and skilled nursing sectors". The analyst keeps his Hold rating on National Health Investors given its premium valuation relative to its peers.
SPG Simon Property
$170.47

-3.95 (-2.26%)

02/08/19
WELS
02/08/19
NO CHANGE
WELS
Wells downgrades Regional Mall REIT sector to Market Weight from Overweight
Wells Fargo analyst Jeffrey Donnelly reduced his rating on the Regional Mall REIT sector to Market Weight from Overweight. The ongoing "revenue disruption" from small-shop and anchor turnover combined with the anchor redevelopment initiatives will be a persistent source of earnings pressure in 2019 and 2020, Donnelly tells investors in a research note. Amid "low and decelerating" core earnings growth relative to other property types, the analyst believes "all but the very best capitalized companies may continue to trade as value ideas." He views Simon Property (SPG) as the dominant global player due to its "strong liquidity, robust balance sheet capacity, high-quality assets, and the depth of personnel capable of undertaking extensive redevelopment programs." Donnelly this morning also downgraded Macerich (MAC) to Market Perform from Outperform and kept an Underperform rating on CBL & Associates (CBL).
02/15/19
MZHO
02/15/19
DOWNGRADE
Target $193
MZHO
Neutral
Simon Property downgraded to Neutral from Buy at Mizuho
Mizuho analyst Haendel St. Juste downgraded Simon Property Group to Neutral with a $193 price target citing valuation. The analyst believes the shares are fairly valued following their "massive outperformance" versus Mall REIT peers since the start of 2018. Further, he sees a "decelerating" earnings profile into 2019 for Simon Property.
10/16/18
SCOT
10/16/18
INITIATION
Target $177
SCOT
Sector Perform
Simon Property initiated with a Sector Perform at Scotiabank
Scotiabank analyst Nicholas Yulico initiated Simon Property with a Sector Perform and $177 price target.
CBL CBL & Associates
$1.09

-0.135 (-11.02%)

08/07/18
BTIG
08/07/18
DOWNGRADE
Target $2.5
BTIG
Sell
CBL & Associates downgraded to Sell from Neutral at BTIG
BTIG analyst James Sullivan downgraded CBL & Associates to Sell from Neutral with a price target of $2.50 after the company warned in its earnings call that a dividend cut in FY19 is possible. The analyst cites the REIT's declining same-store net operating income, capital needs of its portfolio, and a high debt load while re-negotiating its bank lines ahead of a maturing term loan facility next year. Sullivan adds that while CBL's guidance implies some improvement in the second half of this year, its "weaker sales productivity" suggests that the rebound will be more shallow than that of its peers, anticipating a dividend cut of 30%-50%.
12/19/18
JPMS
12/19/18
DOWNGRADE
JPMS
Underweight
CBL & Associates downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Anthony Paolone downgraded CBL & Associates to Underweight. In addition to moving to a less constructive stance on the mall REITs as a group, the analyst believes that CBL's earnings growth will continue to be impacted in the near term by the carryover of headwinds from recent bankruptcies, rent reductions, and co-tenancy issues.
BRX Brixmor
$17.96

-0.16 (-0.88%)

10/16/18
SCOT
10/16/18
INITIATION
Target $18
SCOT
Outperform
Brixmor initiated with an Outperform at Scotiabank
Scotiabank analyst Nicholas Yulico initiated Brixmor with an Outperform and $18 price target.
10/29/18
KEYB
10/29/18
UPGRADE
KEYB
Overweight
Brixmor upgraded to Overweight from Sector Weight at KeyBanc
02/11/19
MUFG
02/11/19
NO CHANGE
Target $19
MUFG
Overweight
Brixmor operating income inflects, says MUFG
MUFG analyst Karin Ford kept her Overweight rating and $19 price target on Brixmor after its Q4 results, saying that the earnings miss was the result of the SEC settlement impact while its FFO on a normalized basis was in line. With the company launching its FY20 guidance, the analyst also points to the midpoint 3.0% growth outlook in its same-store net operating income in spite of the 50bp headwind from Sears bankruptcy.
12/19/18
JPMS
12/19/18
DOWNGRADE
Target $17.5
JPMS
Neutral
Brixmor downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Anthony Paolone downgraded Brixmor Property Group to Neutral and lowered his price target for the shares to $17.50 from $19. While the analyst sees the stock as attractively valued, he believes its near-term FFO growth "should be fairly muted" as a result of heavy recent disposition activity.
KIM Kimco Realty
$17.96

-0.12 (-0.66%)

04/01/19
EVER
04/01/19
DOWNGRADE
EVER
Underperform
Kimco Realty downgraded to Underperform from In Line at Evercore ISI
04/01/19
EVER
04/01/19
DOWNGRADE
Target $17
EVER
Underperform
Kimco Realty downgraded to Underperform on valuation at Evercore ISI
As previously reported, Evercore ISI downgraded Kimco Realty to Underperform from In Line with a $17 price target. Analyst Steve Sakwa said shares have outperformed year-to-date and expects Q2 commentary to be more of uncertainty/caution due to potential store closures.
11/15/18
EVER
11/15/18
UPGRADE
EVER
In Line
Kimco Realty upgraded to In Line from Underperform at Evercore ISI
ALEX Alexander & Baldwin
$23.22

-0.03 (-0.13%)

UBP Urstadt Biddle Properties Inc.
$17.80

(0.00%)

HHC Howard Hughes
$105.79

-2.99 (-2.75%)

08/10/18
JEFF
08/10/18
NO CHANGE
Target $160
JEFF
Buy
Howard Hughes investment thesis remains intact, says Jefferies
Jefferies analyst Omotayo Okusanya says Howard Hughes' investment thesis remains intact despite the "soft" Q2 results. The post-earnings stock selloff "seems overdone" as the earnings miss was either timing related or due to one-off items, Okusanya tells investors in a research note. The analyst sees "strong longer-term growth given the strong pre-leasing in condo towers under development." He reiterates a Buy rating on Howard Hughes and reduced his price target for the shares to $160 from $170.
06/19/18
SBSH
06/19/18
INITIATION
SBSH
Buy
Howard Hughes assumed with a Buy at Citi
Citi analyst Scott Schrier assumed coverage of Howard Hughes with a Buy rating saying the company continues to ramp up net operating income through its development pipeline, which is self-funded.
07/02/18
JEFF
07/02/18
INITIATION
Target $170
JEFF
Buy
Howard Hughes initiated with a Buy at Jefferies
Jefferies analyst Omotayo Okusanya started Howard Hughes with a Buy rating and $170 price target. The analyst believes the company's three main business segments, operating assets, master planned communities and strategic development, can drive meaningful net asset value and free cash flow growth in the coming years.
07/02/18
07/02/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Howard Hughes (HHC) initiated with a Buy at Jefferies. 2. Celyad (CYAD) initiated with a Buy at H.C. Wainwright. 3. Veoneer (VNE) initiated with a Sector Perform at RBC Capital. 4. Melinta Therapeutics (MLNT) initiated with an Overweight at Cantor Fitzgerald. 5. Axon (AAXN) initiated with an Overweight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

VTR

Ventas

$68.60

-0.01 (-0.01%)

07:13
06/19/19
06/19
07:13
06/19/19
07:13
Recommendations
Ventas analyst commentary  »

Ventas price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$3.69

0.06 (1.65%)

07:13
06/19/19
06/19
07:13
06/19/19
07:13
Hot Stocks
Sorrento Therapeutics says Phase 1b resiniferatoxin trial met day 84 goals »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTR

Ventas

$68.60

-0.01 (-0.01%)

07:13
06/19/19
06/19
07:13
06/19/19
07:13
Hot Stocks
Ventas Investor Day presentation sees 'core portfolio growth' through 2024 »

Sees 5%-7% FFO and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USCR

U.S. Concrete

$47.49

-0.78 (-1.62%)

07:13
06/19/19
06/19
07:13
06/19/19
07:13
Conference/Events
U.S. Concrete management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

  • 13

    Nov

FCAU

Fiat Chrysler

$13.49

0.11 (0.82%)

07:12
06/19/19
06/19
07:12
06/19/19
07:12
Initiation
Fiat Chrysler initiated  »

Fiat Chrysler reinstated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

NCMI

National CineMedia

$6.44

-0.03 (-0.46%)

07:11
06/19/19
06/19
07:11
06/19/19
07:11
Upgrade
National CineMedia rating change  »

National CineMedia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

MDB

MongoDB

$166.49

1.27 (0.77%)

07:11
06/19/19
06/19
07:11
06/19/19
07:11
Recommendations
MongoDB analyst commentary  »

MongoDB bulls likely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

AXTA

Axalta Coating

$25.82

0.03 (0.12%)

07:10
06/19/19
06/19
07:10
06/19/19
07:10
Hot Stocks
Axalta Coating up 14% after announcing review of strategic alternatives »

In pre-market trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:10
06/19/19
06/19
07:10
06/19/19
07:10
General news
FX Update: The dollar has seen moderate softness »

FX Update: The dollar has…

NBRV

Nabriva Therapeutics

$2.11

0.045 (2.18%)

07:09
06/19/19
06/19
07:09
06/19/19
07:09
Hot Stocks
Nabriva Therapeutics submits Type A Meeting Request to FDA for CONTEPO »

Nabriva Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

ADBE

Adobe

$276.80

1.21 (0.44%)

07:09
06/19/19
06/19
07:09
06/19/19
07:09
Upgrade
Adobe rating change  »

Adobe upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$3.69

0.06 (1.65%)

07:08
06/19/19
06/19
07:08
06/19/19
07:08
Hot Stocks
Sorrento Therapeutics CEO to provide updates on CD38 immunotherapies »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTEC

Intec Pharma

$4.78

-0.02 (-0.42%)

07:07
06/19/19
06/19
07:07
06/19/19
07:07
Hot Stocks
Intec Pharma's Accordion Pill meets primary endpoint in PK study »

Intec Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMPH

KemPharm

$1.82

0.13 (7.69%)

07:07
06/19/19
06/19
07:07
06/19/19
07:07
Initiation
KemPharm initiated  »

KemPharm initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCRB

Seres Therapeutics

$2.61

0.16 (6.53%)

07:06
06/19/19
06/19
07:06
06/19/19
07:06
Hot Stocks
Seres Therapeutics provides statement regarding FDA safety alert for FMT use »

Seres Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$276.80

1.21 (0.44%)

07:06
06/19/19
06/19
07:06
06/19/19
07:06
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUB

Cubic

$60.46

1.205 (2.03%)

07:04
06/19/19
06/19
07:04
06/19/19
07:04
Hot Stocks
Cubic announces sale of commercial properties in San Diego, Orlando for $46M »

Cubic announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYX

Systemax

$20.56

0.16 (0.78%)

07:03
06/19/19
06/19
07:03
06/19/19
07:03
Conference/Events
Systemax management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

  • 25

    Sep

PLXP

PLx Pharma

$4.93

-0.07 (-1.40%)

07:03
06/19/19
06/19
07:03
06/19/19
07:03
Hot Stocks
PLx Pharma says 'on track' to file VAZALORE submission by year-end »

PLx Pharma announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDB

MongoDB

07:03
06/19/19
06/19
07:03
06/19/19
07:03
Recommendations
MongoDB analyst commentary  »

MongoDB price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

SMLP

Summit Midstream

$6.90

0.13 (1.92%)

07:03
06/19/19
06/19
07:03
06/19/19
07:03
Downgrade
Summit Midstream rating change  »

Summit Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PT

Pintec Technology

$4.38

-0.04 (-0.90%)

07:02
06/19/19
06/19
07:02
06/19/19
07:02
Hot Stocks
Pintec Technology expands partnership with 1an.com »

Pintec Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:02
06/19/19
06/19
07:02
06/19/19
07:02
General news
MBA Mortgage Applications Composite Index data reported »

Week of 6/14 MBA Mortgage…

CTLT

Catalent

$50.48

-0.1 (-0.20%)

, BMY

Bristol-Myers

$47.79

-0.42 (-0.87%)

07:02
06/19/19
06/19
07:02
06/19/19
07:02
Hot Stocks
Catalent tu purchase Bristol-Myers' manufacturing facility in Italy »

Catalent (CTLT) has…

CTLT

Catalent

$50.48

-0.1 (-0.20%)

BMY

Bristol-Myers

$47.79

-0.42 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 16

    Sep

AXTA

Axalta Coating

$25.82

0.03 (0.12%)

07:02
06/19/19
06/19
07:02
06/19/19
07:02
Hot Stocks
Axalta Coating initiates review of strategic alternatives »

Axalta Coating announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.